Medical College of Wisconsin

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Retrieved on: 
Thursday, April 4, 2024
Logic, LN, Transplant, Medical College of Wisconsin, Rachel Haurwitz, Infection, Lupus, Risk, Medical college, Patient, Inflammation, Tissue, Autoimmune disease, Standard of care, Doctor of Philosophy, MD, Autoantibody, IND, Congress, HLA, Reindeer, Antibody, CRISPR, Safety, Immune system, Fatigue, FDA, Lupus nephritis, Autoimmunity, Bone marrow, ERL, Medicine, CD19, Food, PD-1, Pharmaceutical industry

BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.

Key Points: 
  • The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
  • CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion.
  • CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
  • Instead, the chRDNA technology allows for precise insertion of the CAR at an intended location within the T cell genome.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

Herzing University and Medical College of Wisconsin Forge Strategic Partnership to Launch Innovative 4+1 Program

Retrieved on: 
Wednesday, March 13, 2024
Transfer, Master, Postgraduate education, Medical College of Wisconsin, Public health, Partnership, Medical college, Public, MCW, Research, BSHS, University, Doctor of Philosophy, Faculty, Herzing University, Student, MPH, Curriculum, Criterion, GPA, School, Nursing

MILWAUKEE, March 13, 2024 /PRNewswire/ -- Herzing University and the Medical College of Wisconsin (MCW) are excited to announce a pioneering collaboration aimed at providing students with a streamlined route to obtain both undergraduate and graduate degrees in five years. The newly established 4+1 Program integrates Herzing University's Bachelor of Science in Health Sciences (BSHS) curriculum with MCW's renowned Master of Public Health (MPH) Program, offering direct admission to qualified BSHS students.

Key Points: 
  • The 4+1 Program is a five-year dual degree initiative designed to facilitate seamless transition for eligible Herzing University students into the Master of Public Health Program at MCW's School of Graduate Studies.
  • "At Herzing University, we're committed to providing innovative pathways for our students to excel in the ever-evolving healthcare landscape," said Dr. Sarah Olson, PhD, Program Chair – Healthcare Management/Healthcare Administration & Health Sciences, Herzing University.
  • "The Medical College of Wisconsin is excited to partner with Herzing University in launching the 4+1 Program, which represents a significant step forward in our joint efforts to cultivate the next generation of public health leaders," said Kim Contardi, MPH, MPH Program Manager, Medical College of Wisconsin.
  • The collaboration between Herzing University and the Medical College of Wisconsin represents a significant step forward in advancing healthcare education and preparing future leaders in public health.

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Retrieved on: 
Thursday, March 7, 2024
SAN, Medical college, Medical College of Wisconsin, Vancouver General Hospital, DSM-IV codes, American College, ACMG, OGM, LGG, Medical genetics, DRS, Research, Cancer, Medical device

Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis

Key Points: 
  • Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
    A scientific platform presentation will feature Drs.
  • ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.
  • The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.
  • All scientific posters will be presented in Exhibit Halls DE.

Wisconsin's Drive for $75M Towards Personalized Medicine Innovation

Retrieved on: 
Thursday, February 29, 2024
CHIPS, Senior, Entrepreneurship, Research, Medical college, Medical College of Wisconsin, Health, Growth, Economy, Data science, Phase II, EDA, Milwaukee Area Technical College, Madison College, Strategic planning, Patient, Automation, University City (Charlotte neighborhood), GE HealthCare, University of Wisconsin–Madison, Health equity, State, Science, Workforce, Assistant professor, Pathway

Image-Guided Therapy Data-Centric Patient Care Pathway- streamlines the integration of new technologies into healthcare systems, supporting the growth of theranostics and driving innovation in personalized medicine.

Key Points: 
  • Image-Guided Therapy Data-Centric Patient Care Pathway- streamlines the integration of new technologies into healthcare systems, supporting the growth of theranostics and driving innovation in personalized medicine.
  • Wisconsin Biohealth Tech Hub Governance- nurtures collaboration across projects, tracks metrics, and shares learnings, reinforcing the cycle of innovation and deployment.
  • "Receiving the Tech Hub designation was just the beginning," explains Wendy Harris , Regional Innovation Officer for the Wisconsin Biohealth Tech Hub .
  • "It recognizes Wisconsin's strengths in personalized medicine, biohealth technology, and precision manufacturing.

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

Retrieved on: 
Wednesday, December 6, 2023
Research, Surgery, Hospitals, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Harold Fowler McCormick, GMP, Hope, Therapy, Northwestern University, CDMO, Transplant, Patient, Multimedia, FDA, Autoimmune disease, Cell engineering, Medical College of Wisconsin, Organ transplantation, MD, CGMP, Partnership, Doctor of Philosophy, Medical college, Phase II, Quality of life, Pharmaceutical industry

Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.

Key Points: 
  • Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.
  • View the full release here: https://www.businesswire.com/news/home/20231206255985/en/
    This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform.
  • "We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options," said Cyrus Yang, COO of Taiwan Bio.
  • Our Phase 2 trial represents a significant step forward in our mission to provide solid organ transplant patients with better treatment options."

Prytime Medical Announces Appointment of Robert A. Cohen, M.D., to its Clinical Advisory Board

Retrieved on: 
Wednesday, November 22, 2023
Placenta, Research, SAN, Gynaecology, Medical director, Bleeding, Placenta accreta spectrum, Patient, Obstetrics, REBOA, University, Mother, Medical City Dallas Hospital, Medical City, Medical college, PAS, Physician, Medical College of Wisconsin, Medical device

SAN ANTONIO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products announced that board-certified obstetrician-gynecologist Robert A. Cohen, M.D., has joined the company's Clinical Advisory Board effective immediately.

Key Points: 
  • Dr. Cohen is the Medical Director of the Placenta Accreta Program at Medical City Dallas and is also a member of the AOA Honor Medical Society.
  • He is invested in research and recently published a paper on improved placement location of REBOA catheter in pelvic hemorrhage.
  • "Dr. Cohen joins the Prytime team as a highly recognized leader in the industry and brings first-hand clinical experience that transcends obstetrics," said David Spencer, Prytime Medical Devices, Inc.'s CEO.
  • Dr. Cohen received his medical degree from Medical College of Wisconsin and completed residency at the University of Texas Southwestern Medical Center.

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Research, Clinical Trials, Biotechnology, Biometrics, Health, General Health, Other Science, Science, Oncology, Interventional pulmonology, High, Critical care, Comparison, HT, Medical college, ORACLE, Cancer, Lung cancer, Medical school, DO, Medical University of South Carolina, MD, Learning, Medical College of Wisconsin, Annual general meeting, PET/CT, Medical device, Medical imaging

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.
  • These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules.
  • Dr. Kurman, remarked, "The data we're presenting at CHEST 2023 underscores the transformative potential of the Nodify XL2 test in managing all types of lung nodules.
  • However, published data shows that the performance of PET/CT imaging alone is compromised in assessing small lung nodules for cancer.

Edward Owusu Kwarteng, Ph.D., BSc, MSc, Honored With The 2023 ASH-CIBMTR-ASTCT Career Development Award

Retrieved on: 
Monday, October 2, 2023
University of Texas Southwestern Medical Center, National Marrow Donor Program, University, MCW, ASH, Senior, Virology, Medical college, Exposition, Transplant, Cell, Stem cell, Bachelor of Science, Health, University of Cape Coast, Glycolysis, Metabolism, MD, Patient, NMDP, Master of Science, Diversity, Medical College of Wisconsin, Inclusion, INRS, B cell, Society, Synthetic biology, Hematopoietic stem cell transplantation, Nursing, Hematology, Research

This award is exclusively for clinical and translational researchers who plan to practice hematopoietic stem cell transplantation and cellular therapy clinical patient care.

Key Points: 
  • This award is exclusively for clinical and translational researchers who plan to practice hematopoietic stem cell transplantation and cellular therapy clinical patient care.
  • The CIBMTR is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW).
  • The award is part of a program to increase racial and ethnic diversity in the next generation of medical professionals.
  • Dr. Kwarteng receives registration for the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

Montecito Medical Acquires Medical Office Property in Milwaukee Area

Retrieved on: 
Wednesday, September 20, 2023
Health, Other Construction & Property, Hospitals, Other Health, Commercial Building & Real Estate, Managed Care, Construction & Property, Medicine, MCW, Senior, Medical college, ALM (company), Multimedia, Froedtert Hospital, Montecito, Medical College of Wisconsin, Hospital, Acquisition, Internet, Patient, Physician, Nursing, Investment, Milwaukee metropolitan area

Montecito Medical, a leading acquirer of medical office properties nationwide, has acquired a 12,600-square-foot medical office building in West Allis, Wisconsin.

Key Points: 
  • Montecito Medical, a leading acquirer of medical office properties nationwide, has acquired a 12,600-square-foot medical office building in West Allis, Wisconsin.
  • View the full release here: https://www.businesswire.com/news/home/20230920456811/en/
    The Lincoln Avenue Health Center building is 100% leased to Medical College of Wisconsin, a market-dominant group in the Greater Milwaukee area.
  • Medical College of Wisconsin (MCW) physicians and practitioners provide primary and specialty care at many hospitals and clinics in metro Milwaukee and eastern Wisconsin.
  • Montecito Medical is one of the nation’s largest privately held companies specializing in healthcare-related real estate acquisitions and partnering with physicians and developers to fund development of medical real estate.